D. Boral Capital Reiterates Buy Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reissued by D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $2.00 target price on the stock. D. Boral Capital’s price objective would indicate a potential upside of 238.98% from the stock’s current price.

Several other equities analysts also recently weighed in on RVPH. HC Wainwright lowered their target price on Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Chardan Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Benchmark cut their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ RVPH opened at $0.59 on Tuesday. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17. The firm has a market capitalization of $67.89 million, a price-to-earnings ratio of -1.28 and a beta of -0.02. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $0.52.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. Sell-side analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the first quarter valued at approximately $58,000. XTX Topco Ltd purchased a new position in shares of Reviva Pharmaceuticals in the second quarter worth $31,000. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the third quarter worth $37,000. Finally, Millennium Management LLC boosted its position in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.